These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2190011)

  • 1. Therapeutic effects of cefpirome, a new cephalosporin, on various models of infections in mice and rats.
    Arai S; Kobayashi S; Hayashi S
    Jpn J Antibiot; 1990 Jan; 43(1):1-8. PubMed ID: 2190011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic.
    Kasai K; Tsuji A; Miyazaki S; Goto S; Fujimoto K; Masuyoshi S; Arai S
    Jpn J Antibiot; 1984 Jul; 37(7):1306-12. PubMed ID: 6092740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987). I. Susceptibility distribution].
    Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1990 Jun; 43(6):919-53. PubMed ID: 2122040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Wakai Y; Kamimura T; Tawara S; Matsumoto S; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):88-98. PubMed ID: 8436563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus.
    Hanaki H; Akagi H; Masaru Y; Otani T; Hyodo A; Hiramatsu K
    Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin].
    Chantot JF; Bryskier A
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):482-6. PubMed ID: 3937124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.
    Arai S; Hayashi S
    Infection; 1990; 18(3):186-90. PubMed ID: 2194972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
    Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
    Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis.
    Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R
    J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
    Ida T; Tsushima M; Ishii T; Atsumi K; Tamura A
    J Infect Chemother; 2002 Jun; 8(2):138-44. PubMed ID: 12111566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experimental infections in mice.
    Iizawa Y; Okonogi K; Hayashi R; Iwahi T; Yamazaki T; Imada A
    Antimicrob Agents Chemother; 1993 Jan; 37(1):100-5. PubMed ID: 8431004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
    Tsuji M; Takema M; Miwa H; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2507-12. PubMed ID: 12878512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983].
    Matsuo K; Tsuzaki Y; Furukawa S; Uete T
    Jpn J Antibiot; 1984 Jun; 37(6):1040-57. PubMed ID: 6387213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1987). III. Secular changes in susceptibility].
    Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1990 Jun; 43(6):968-1136. PubMed ID: 2122041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.